Chemical Structure : Quisinostat
CAS No.: 875320-29-9
Catalog No.: PC-21412Not For Human Use, Lab Use Only.
Quisinostat (JNJ-26481585) is potent, second-generation histone deacetylase (HDAC) inhibitor with IC50 of 0.11 nM-0.64 nM for HDAC1, HDAC2, HDAC4, HDAC10 and HDAC11.
Packing | Price | Stock | Quantity |
---|---|---|---|
10 mg | $198 | In stock | |
25 mg | $328 | In stock | |
50 mg | $528 | In stock | |
100 mg | Get quote |
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
Quisinostat (JNJ-26481585) is potent, second-generation histone deacetylase (HDAC) inhibitor with IC50 of 0.11 nM-0.64 nM for HDAC1, HDAC2, HDAC4, HDAC10 and HDAC11.
Quisinostat (JNJ-26481585) induced caspase cascade activation and upregulation of p21, resulting in apoptosis and cell cycle arrest in the myeloma cells at low nanomolar concentrations.
JNJ-26481585 had a potent anti-MM activity that can overcome the stimulatory effect of the BM microenvironment in vivo.
Quisinostat (JNJ-26481585) fully inhibited the growth of C170HM2 colorectal liver metastases, shows broad-spectrum preclinical antitumoral activity.
M.Wt | 394.48 | |
Formula | C21H26N6O2 | |
Appearance | Solid | |
Storage |
|
|
Solubility |
10 mM in DMSO |
|
Chemical Name/SMILES |
N-Hydroxy-2-(4-((((1-methyl-1H-indol-3-yl)methyl)amino)methyl)piperidin-1-yl)pyrimidine-5-carboxamide |
1. Deleu S, et al. Leukemia. 2009 Oct;23(10):1894-903.
2. Deleu S, et al. Cancer Res. 2009 Jul 1;69(13):5307-11.
3. Arts J, et al. Clin Cancer Res. 2009 Nov 15;15(22):6841-51.
Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright